Chargement en cours...
Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib
Despite the huge success of tyrosine kinase inhibitors as anticancer agents, severe side effects are a major problem. In order to overcome this drawback, the first hypoxia-activatable 2-nitroimidazole-based prodrugs of the clinically approved ALK and c-MET inhibitor crizotinib were developed. The 2-...
Enregistré dans:
| Publié dans: | Bioorg Chem |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7611434/ https://ncbi.nlm.nih.gov/pubmed/32229347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bioorg.2020.103778 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|